Tunicamycins, which are nucleoside natural products, inhibit both bacterial phospho-Nacetylmuraminic acid (MurNAc)-pentapeptide translocase (MraY) and human UDP-Nacetylglucosamine (GlcNAc): polyprenol phosphate translocase (GPT). The improved synthesis and detailed biological evaluation of an MraY-selective inhibitor, 2, where the GlcNAc moiety was modified to a MurNAc amide, has been described.